Evidence of a TH1 type response associated with recurrent miscarriage

Evidence of a TH1 type response associated with recurrent miscarriage
复制标题

DOI:
10.1016/s0015-0282(00)00517-3
复制
发表时间:
2000-06-01
影响因子:
6.7
通讯作者:
Walker, JJ
Walker, JJ
中科院分区:
医学2区
文献类型:
--
作者:
Jenkins, C;Roberts, J;Walker, JJ

文献摘要

被引文献

相似文献

目的:确定t - h1细胞因子干扰素(IFN)- γ是否与流产相关,而t - h2细胞因子白细胞介素(IL)-10是否与妊娠成功相关。设计:对照临床研究。环境:学术环境中的健康志愿者。患者:第一组包括10名非孕妇;第2组,10名早期妊娠妇女;第3、10组为自然流产的初孕妇女;第4组,第10组有流产史的早期妊娠妇女。所有妇女在抽样时都怀孕了,但有5人在妊娠早期流产。干预:所有患者均未接受任何药物治疗。主要观察指标:血清IL-10和ifn - γ水平。结果:正常妊娠组IL-10水平明显升高。与正常妊娠相比,复发流产组的ifn - γ水平升高。当第4组的患者被分为足月妊娠组和流产组时,我们发现,成功妊娠与IL-10水平的显著升高相关,而流产与ifn - γ水平的显著升高相关。结论:这些结果支持流产与t - h1型反应相关的观点。(C) 2000年,美国生殖医学学会。)
Objective: To determine whether the T-H 1 cytokine interferon (IFN)-gamma is associated with miscarriage whereas the T-H 2 cytokine interleukin (IL)-10 is associated with successful pregnancy.Design: Controlled clinical study.Setting: Healthy volunteers in an academic setting.Patient(s): Group 1 comprised 10 nonpregnant women; group 2, 10 first-trimester primigravid women; group 3, 10 first-trimester primigravid women suffering spontaneous abortion; and group 4, 10 first-trimester pregnant women with a history of miscarriage. All women were pregnant at the time of sampling, but 5 miscarried later in the first trimester.Intervention(s): None of the patients received any medication.Main Outcome Measure(s): Serum levels of IL-10 and IFN-gamma.Result(s): Levels of IL-10 were significantly raised in normal pregnancy. Levels of IFN-gamma were raised in the recurrent-miscarriage group as compared with normal pregnancy. When patients in group 4 were divided into those whose pregnancies went to term and those who miscarried, we found that successful pregnancy was associated with a statistically significant increase in IL-10, whereas miscarriage was associated with significantly increased levels of IFN-gamma.Conclusion(s): These results support the view that miscarriage is associated with a T-H 1 type response. ((C) 2000 by American Society for Reproductive Medicine.)